DexCom, Inc. $DXCM Position Lowered by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 97.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,009 shares of the medical device company’s stock after selling 2,377,425 shares during the period. Jefferies Financial Group Inc.’s holdings in DexCom were worth $5,092,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Mather Group LLC. increased its stake in shares of DexCom by 27.7% during the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock worth $49,000 after purchasing an additional 122 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its holdings in DexCom by 2.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after acquiring an additional 150 shares during the period. Elevation Wealth Partners LLC boosted its holdings in DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 153 shares during the period. Finally, Simplicity Wealth LLC grew its position in shares of DexCom by 5.4% in the third quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock valued at $273,000 after purchasing an additional 162 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings upgraded DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Royal Bank Of Canada restated an “outperform” rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Evercore raised their target price on DexCom from $90.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Leerink Partners dropped their price target on DexCom from $94.00 to $87.00 and set an “outperform” rating on the stock in a research report on Monday, October 26th. Finally, UBS Group lifted their price target on DexCom from $102.00 to $107.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $95.50.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 2,565 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total transaction of $201,660.30. Following the completion of the sale, the executive vice president directly owned 120,913 shares of the company’s stock, valued at $9,506,180.06. The trade was a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the sale, the executive vice president directly owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 22,822 shares of company stock worth $1,920,193. 0.28% of the stock is owned by insiders.

DexCom Price Performance

Shares of DexCom stock opened at $81.39 on Friday. DexCom, Inc. has a twelve month low of $56.72 and a twelve month high of $92.59. The firm has a market cap of $30.35 billion, a P/E ratio of 30.09, a price-to-earnings-growth ratio of 1.33 and a beta of 1.45. The firm’s 50-day simple moving average is $84.43 and its 200-day simple moving average is $75.16. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. DexCom’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. As a group, research analysts expect that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.